The primary purpose of this study is to compare the effect of double doses of a study drug known as insulin peglispro and insulin glargine in participants who have type 2 diabetes. Participants will be treated for up to 11 weeks, and will take part in two study periods. Each participant will receive insulin peglispro during one treatment period and insulin glargine during the other treatment period.